- Home
- PARR vs TARS Comparison
PARR vs TARS Comparison
Compare PARR & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PARR | TARS |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PARR | TARS |
|---|---|---|
| Price | $52.53 | $60.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $70.17 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 898.7K | 466.4K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | 48.21 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $2,443,066,000.00 | $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | $3.78 | $30.19 |
| P/E Ratio | $48.62 | ★ N/A |
| Revenue Growth | 30.99 | ★ 146.71 |
| 52 Week Low | $26.41 | $38.51 |
| 52 Week High | $70.39 | $85.25 |
Technical Indicators
Market Signals| Indicator | PARR | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 46.26 |
| Support Level | $33.67 | $56.90 |
| Resistance Level | $59.08 | $67.24 |
| Average True Range (ATR) | 2.37 | 2.61 |
| MACD | -0.22 | 0.37 |
| Stochastic Oscillator | 12.66 | 52.62 |
Price Performance
Historical ComparisonAbout PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments: Refining. Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operating licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.